LIMN (Liminatus Pharma) Non Operating Income: $-8.39 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $3.84
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Non Operating Income?

Liminatus Pharma LIMN +5.35% 13 Non Operating Income is $-8.39 Mil as of Jun. 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Liminatus Pharma's Non Operating Income for the three months ended in Jun. 2026 was $-0.02 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-8.39 Mil.

Liminatus Pharma Non Operating Income Related Terms

Liminatus Pharma Non Operating Income Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma Non Operating Income Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Non Operating Income
0.00 0.00 0.00 -7.10

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.27 -1.10 -7.27 -0.00 -0.02
LIMN
13GF Score
Liminatus Pharma Inc LIMN
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liminatus Pharma Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-8.39 Mil mean?
Liminatus Pharma (LIMN) has a Non Operating Income of $-8.39 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Liminatus Pharma and its competitors.
Is Liminatus Pharma's Non Operating Income too high?
Liminatus Pharma's current Non Operating Income is $-8.39 Mil. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Non Operating Income compare to NIKI and KAPA?
Liminatus Pharma's Non Operating Income of $-8.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current Non Operating Income is $-8.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Non Operating Income of $-8.39 Mil. The current Non Operating Income is $-8.39 Mil. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Non Operating Income is $-8.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price